KA
GILD icon

Klingman & Associates’s Gilead Sciences GILD Stock Holding History

Klingman & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$337K Buy
2,664
+19
+0.7% +$2.5K 0.01% 252
2026
Q1 		$369K Buy
2,645
+119
+5% +$16.7K 0.02% 233
2025
Q4 		$310K Buy
2,526
+211
+9% +$25.6K 0.02% 250
2025
Q3 		$257K Buy
+2,315
New +$263K 0.01% 285
2016
Q4 		– Sell
-100
Closed -$8K – 180
2016
Q3 		$8K Hold
100
– – ﹤0.01% 302
2016
Q2 		$8K Hold
100
– – ﹤0.01% 306
2016
Q1 		$9K Hold
100
– – ﹤0.01% 300
2015
Q4 		$10K Hold
100
– – ﹤0.01% 301
2015
Q3 		$9K Hold
100
– – ﹤0.01% 313
2015
Q2 		$12K Hold
100
– – ﹤0.01% 294
2015
Q1 		$10K Buy
+100
New +$10.2K ﹤0.01% 277

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Klingman & Associates's GILD Position: Q2 2026 in Review

Klingman & Associates increased its Gilead Sciences (GILD) stake by 0.72% in Q2 2026, buying an estimated $2.5K and bringing the position to 2,664 shares worth $337K. The position accounts for 0.01% of the portfolio, ranked #252.

Klingman & Associates first reported a position in GILD in Q1 2015 and has held it in 11 quarters since. The position peaked at $369K in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Klingman & Associates held 2,664 shares of Gilead Sciences worth $337K as of Q2 2026.
  • Klingman & Associates bought 19 Gilead Sciences shares in Q2 2026, an estimated $2.5K.
  • Gilead Sciences made up 0.01% of Klingman & Associates's portfolio in Q2 2026, its #252 holding.
  • Klingman & Associates first reported a position in Gilead Sciences in Q1 2015 and has held it in 11 quarters since.
  • Klingman & Associates's Gilead Sciences position peaked at $369K in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Klingman & Associates's 13F filing for Q2 2026, filed 29 Jul 2026.